Targeted FGFR blockade for the treatment of tumor-induced osteomalacia
IR Hartley, CB Miller, GZ Papadakis… - … England Journal of …, 2020 - Mass Medical Soc
New England Journal of Medicine, 2020•Mass Medical Soc
Targeted FGFR Blockade for Tumor-Induced Osteomalacia This letter describes the
treatment of a patient with tumor-induced osteomalacia due to a phosphaturic mesenchymal
tumor. The discovery of FN1–FGFR1 fusion genes in such tumors has led to the
identification of fibroblast growth factor receptor 1 as a potential therapeutic target. Here, the
use of infigratinib, an FGFR1–3 tyrosine kinase inhibitor, decreased bone lesions.
treatment of a patient with tumor-induced osteomalacia due to a phosphaturic mesenchymal
tumor. The discovery of FN1–FGFR1 fusion genes in such tumors has led to the
identification of fibroblast growth factor receptor 1 as a potential therapeutic target. Here, the
use of infigratinib, an FGFR1–3 tyrosine kinase inhibitor, decreased bone lesions.
Targeted FGFR Blockade for Tumor-Induced Osteomalacia
This letter describes the treatment of a patient with tumor-induced osteomalacia due to a phosphaturic mesenchymal tumor. The discovery of FN1–FGFR1 fusion genes in such tumors has led to the identification of fibroblast growth factor receptor 1 as a potential therapeutic target. Here, the use of infigratinib, an FGFR1–3 tyrosine kinase inhibitor, decreased bone lesions.
The New England Journal Of Medicine